Evidence map›Paper›PMID 37843765›Full record

GuidelineBreast cancer (Tokyo, Japan)2024

The Japanese Breast Cancer Society Clinical Practice Guidelines for surgical treatment of breast cancer, 2022 edition.

Takehiko Sakai, Goro Kutomi, Tadahiko Shien, Sota Asaga, Tomoyuki Aruga, Makoto Ishitobi, Sayaka Kuba, Masataka Sawaki, Kaori Terata, Koichi Tomita and 4 more

Abstract readPractice Guideline
PubMed Publisher
In one paragraph

Guideline in Breast cancer (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Observational
  11. Review
  12. Article
  13. Axillary lymph node removal inGland surgery · 2024
    Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Takehiko SakaiDepartment of Breast Surgical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. takehiko.sakai@jfcr.or.jp.ORCID http://orcid.org/0000-0002-4982-951X
Goro KutomiDepartment of Surgery, Surgical Oncology and Science, Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan.
Tadahiko ShienDepartment of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan.
Sota AsagaDepartment of Breast Surgery, Keiyu Hospital, Yokohama, Japan.
Tomoyuki ArugaDepartment of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Makoto IshitobiDepartment of Breast Surgery, Mie University School of Medicine, Mie, Japan.
Sayaka KubaDepartment of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Masataka SawakiDepartment of Breast Oncology, Aichi Cancer Center Hospital, Aichi, Japan.
Kaori TerataDepartment of Breast and Endocrine Surgery, Akita University Hospital, Akita, Japan.
Koichi TomitaDepartment of Plastic and Reconstructive Surgery, Kindai University, Osaka, Japan.
Chikako YamauchiDepartment of Radiation Oncology, Shiga General Hospital, Shiga, Japan.
Yutaka YamamotoDepartment of Breast and Endocrine Surgery, Kumamoto University Hospital, Kumamoto, Japan.
Hiroji IwataDepartment of Breast Oncology, Aichi Cancer Center Hospital, Aichi, Japan.
Shigehira SajiDepartment of Medical Oncology, Fukushima Medical University, Fukushima, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 2022 revision of the Japanese Breast Cancer Society (JBCS) Clinical Practice Guidelines for surgical treatment of breast cancer was updated following a systematic review of the literature using the Medical Information Network Distribution Service (MINDS) procedure, which focuses on the balance of benefits and harms for various clinical questions (CQs). Experts in surgery designated by the JBCS addressed five areas: breast surgery, axillary surgery, breast reconstruction, surgical treatment for recurrent and metastatic breast cancer, and other related topics. The revision of the guidelines encompassed 4 CQs, 7 background questions (BQs), and 14 future research questions (FRQs). A significant revision in the 2022 edition pertained to axillary management after neoadjuvant chemotherapy in CQ2. The primary aim of the 2022 JBCS Clinical Practice Guidelines is to provide evidence-based recommendations to empower patients and healthcare professionals in making informed decisions regarding surgical treatment for breast cancer.

Indexed as

Breast NeoplasmsDecision MakingFemaleHumansJapanClinical practice guidelineClinical questionSurgical treatment of breast cancer

Identifiers

PMID37843765

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.